Navigation Links
Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer

discovering promising early drug development opportunities and translating them into successful marketed drugs that target major unmet clinical needs in cancer, inflammation and neurodegenerative disease. The company's two lead programs are entering advanced clinical trials for deadly, late-stage cancers. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform using protein misfolding, identified as a key factor in cancer and neurodegenerative disease, to feed its pipeline of small molecule therapeutic candidates. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit www.reatapharma.com

Contact

For Reata Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828
kathryn@kmorrispr.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Reata Synthetic Triterpenoids Profiled Nature Reviews Cancer
(Date:4/21/2015)... ST. LOUIS , April 21, 2015 ... as a 5.4 percent decrease in utilization helped offset ... according to new data released today by Express Scripts ... Express Scripts Workers, Compensation Drug Trend Report discusses the ... opioid use among injured workers. Opioid ...
(Date:4/21/2015)... , April 21, 2015  The American ... U.S. Food and Drug Administration that the agency,s ... for the last 25 years to protect the ... homeopathic medicines. AAHP, the industry,s trade association, was ... of homeopathic medicines to engage in productive discussions ...
(Date:4/21/2015)... NEW YORK , April 21, 2015 ... of amendments to its Clinical Trial Authorizations (CTAs) filed ... Regulatory Agency (MHRA) and Germany,s ... (BfArM) for the expansion of the Company,s global Phase ... hepatocellular carcinoma (primary liver cancer, or HCC), to include ...
Breaking Medicine Technology:Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4Speakers at FDA Hearing Praise Success of Homeopathic Regulatory Framework 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 3Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 4
... - First prospective biomarker trial in non-small cell ... /PRNewswire-FirstCall/ -- Response,Genetics, Inc. today announced that positive ... issue of the Journal of Clinical,Oncology suggests that ... in patient biopsies,with advanced non-small cell lung cancer ...
... LOS ANGELES--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Society for,Medical Oncology (ESMO) Conference, which is currently ... in two oral and,poster presentations on Sunday, July ...
Cached Medicine Technology:Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6
(Date:4/21/2015)... 2015 As a provider of holistic, ... that their rehabilitation strategy, which involves various treatment modalities, ... In an effort to offer hope and encouragement to ... lives, Best Drug Rehabilitation has featured a series of ... successful graduates of their recovery program. , One ...
(Date:4/21/2015)... Zane Benefits, the leader in individual ... publication of a new guide “Health Reimbursement Accounts in ... the health insurance industry, including how employers can use ... what is permitted when implementing an HRA. This simple, ... which HRAs are compliant this year. , According ...
(Date:4/21/2015)... April 21, 2015 Zane Benefits, a ... today its CEO Rick Lindquist has been selected as ... , According to Rick Lindquist, “There is a massive ... Zane Benefits’ small business solutions are at its forefront. ... by Employee Benefit Adviser’s Rising Stars.” , According to ...
(Date:4/21/2015)... 21, 2015 Optimity Advisors ( ... advisory firm that helps clients in complex industries ... that the Association of Community Affiliated Plans ... ACAP represents 58 local, not-for-profit, community-affiliated Safety Net ... million people primarily enrolled in public or state-sponsored ...
(Date:4/21/2015)... When a bandage sticks to an injury site ... solve this problem two inventors from Festus, Mo., designed ... helps a cut, burn, abrasion or wound heal more ... The bandage is easy to use, versatile and producible ... to the St. Louis office of InventHelp. It is ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Graduate Discusses Making Amends and Rebuilding Relationships 2Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2
... develop certain hereditary cancers develop them at earlier ages than ... CANCER , a peer-reviewed journal of the American Cancer Society, ... of cancer diagnosis to determine when to provide counseling, screening, ... the BRCA genes have a high risk of developing breast ...
... , SATURDAY, Sept. 10 (HealthDay News) -- It,s important for ... their children to do their homework, a new study suggests. ... toward homework improves if parents take a positive, supportive attitude ... the assignment or getting a higher grade. The study ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, ... Administration advisers recommended Friday that osteoporosis drugs such as ... clarifying how long a patient should take a drug ... drugs, known as bisphosphonates, are taken to prevent fractures ...
... Preliminary research on Fusarium , a group of ... shows how these microbes travel through the air. ... research, there will be a better understanding about crop ... are steering their efforts towards a new aerobiological modeling ...
... A new study finds that lung cancer patients ... percentage of uninsured and Medicaid-insured patients, so-called "high ... undergo surgery that was intended to cure the ... burden facilities. This difference persisted even after controlling ...
... , FRIDAY, Sept. 9 (HealthDay News) -- One-third ... inherited metabolic disorder, a new study finds. This ... produced naturally from many foods -- that has a foul, ... a disease that impairs the ability of an enzyme to ...
Cached Medicine News:Health News:Women who inherit BRCA gene mutations develop cancer earlier than their ancestors 2Health News:Parents' Positive Attitude Can Help Kids Get Homework Done 2Health News:FDA Advisers Call for Revised Labels for Osteoporosis Drugs 2Health News:FDA Advisers Call for Revised Labels for Osteoporosis Drugs 3Health News:Microbes travel through the air; it would be good to know how and where 2Health News:Microbes travel through the air; it would be good to know how and where 3Health News:Study finds hospitals of last resort deliver lower quality of lung cancer care 2
... Nidek GYC-1000 delivers a solid-state ... of energy and plugs into ... compact design and extreme portability, ... with the Nidek Phaco Emulsification ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
Medicine Products: